Long-Term Safety and Results Most people tolerate both peptides well, even with long-term use
In general, the self-report data indicate that medication users often report higher doses than those recorded in their EHRs, with 88.8% of semaglutide and 84.3% of tirzepatide users self-reporting a dosage greater or equal to the EHR records
Temporary Fatigue A small percentage of users report experiencing mild fatigue or lightheadedness, in the first few days of use
Modern diagnostics integrate multimodal imaging: ultra-widefield (UWF) retinal imaging captures peripheral lesions, and optical coherence tomography angiography (OCTA) visualizes microvasculature (20, 21)
Billed quarterly - 30 injections (1 ml per inj., as prescribed) 1 Month Plan $93/month *First order, then $109/mo
[2] [5] Understanding the realistic timeline and expected outcomes with GLP-1 therapy is crucial for patient satisfaction and adherence